Skip to product content

ACTIVE PHARMACEUTICAL INGREDIENT

Lenvatinib API

Review the Lenvatinib free-base filing before you request a specification. The supplied FDA snapshot has one Type II Drug Master File whose subject is exactly LENVATINIB. Salt, solvate and named crystal-form subjects stay outside this dataset.

CSV export requires an active subscription. The Lenvatinib filing in the table is already visible. Already subscribed? Sign in to export it.

This profile uses the Lenvatinib free-base identity, CAS 417716-92-8. A record is included only when the reported subject is exactly LENVATINIB after trimming. The workbook has no CAS field, so mesylate, besylate, solvate, route-code and named crystal-form subjects are excluded.

Lenvatinib registration data overview

The supplied FDA snapshot contains 1 Type II record with the subject LENVATINIB. The free table shows that Lenvatinib filing. A subscription exports the same row as CSV and does not unlock another free-base row from this snapshot.

The count describes filings at the June 30, 2026 cutoff. Confirm the current activity status with FDA and the material specification with the holder before relying on the record.

Personal API data subscription

$19.00 per month

$149.00 per year

Billed $149.00 every year

Lenvatinib coverage: 1 FDA DMF record. The free table already shows that filing, and the CSV sample contains the same row.

Subscription benefits and CSV samples
  • Complete available registry records
  • Search and status filters
  • Documented company-name correspondences
  • CSV exports with sources

One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product.

US REGULATORY RECORDS

Lenvatinib FDA Drug Master File

Read DMF 33195 for the reported holder, the initial submission date and the activity status. The holder name is the party listed on the filing. Confirm the manufacturing site separately during qualification. The same holder name also appears on a separate subject that names the mesylate; only this Lenvatinib subject is kept.

FDA DMF records: 1. Distinct reported holders: 1.

1Active (A)

0Inactive (I)

FDA uses A for active and I for inactive. This Lenvatinib entry is active in the snapshot. An active code does not establish permission to reference the file, an approved supplier or an available batch.

Free previewShowing 1 of 1 Lenvatinib records.

  • MSN LABORATORIES PRIVATE LTDDMF number 33195Active (A)Record details
    DMF number
    33195
    Activity status
    Active (A)
    DMF type
    II
    Initial submission
    2018-09-29
    Reported holder
    MSN LABORATORIES PRIVATE LTD
    Reported subject
    LENVATINIB
Inclusion criteria
  • Included 1 Type II entry whose subject equals LENVATINIB after trimming whitespace. Subjects that name a salt, solvate, besylate, crystal form, route code or non-sterile bulk are excluded.
  • All six FDA fields and the original values are retained, with the Excel submission date converted to ISO format. The activity code describes the June 30, 2026 snapshot. The workbook has no CAS field that could confirm the chemical form of an individual filing.

Lenvatinib chemical identity

The FDA substance record identifies Lenvatinib free base by CAS 417716-92-8 and UNII EE083865G2 and lists E7080 as a synonym. PubChem CID 9823820 supplies the free-base formula and a computed molecular weight of 426.9 g/mol, and it lists deprecated CAS 942407-57-0 for the same free base. The LENVIMA label states that the capsule drug substance is the mesylate salt, with a salt molecular weight of 522.96. Capsule strengths of 4 mg and 10 mg are expressed as lenvatinib and equal 4.90 mg and 12.25 mg of the salt. PubChem CID 11237762 assigns that salt CAS 857890-39-2. The October 5, 2026 China CDE export has 23 related entries, all named 甲磺酸仑伐替尼, with 21 status A and 2 status I. The export does not use the free-base name or give a CAS number. Those registrations, and every FDA subject other than LENVATINIB, are outside this record set.

Lenvatinib free-base properties

The formula and molecular weight below describe Lenvatinib free base. The label gives the mesylate salt a molecular weight of 522.96. When comparing specifications, check whether the assay is expressed as the free base or as the salt, and confirm the solid form against the intended material.

Molecular formula
C21H19ClN4O4
PubChem compound CID 9823820
Molecular weight
426.9 g/mol
PubChem compound CID 9823820

Lenvatinib API sourcing questions

What is the CAS number for Lenvatinib free base?

The CAS number is 417716-92-8. FDA identifies this Lenvatinib substance with UNII EE083865G2 and lists E7080 as a synonym. PubChem also lists deprecated CAS 942407-57-0 for the same free base. Use the CAS and the stated chemical form together when requesting a material specification.

How does Lenvatinib free base differ from the mesylate salt?

The salt pairs the protonated base with methanesulfonate. The LENVIMA label identifies the capsule drug substance as that salt and expresses 4 mg and 10 mg strengths as the equivalent amount of lenvatinib, corresponding to 4.90 mg and 12.25 mg of the salt. PubChem assigns the salt CAS 857890-39-2. Mesylate, besylate, solvate and named crystal-form filings are outside this Lenvatinib record set.

Which FDA DMF record is included for Lenvatinib?

The Q2 2026 workbook contains 1 Type II entry whose full subject is LENVATINIB after trimming. That filing is DMF 33195, reported holder MSN LABORATORIES PRIVATE LTD, first submitted on 2018-09-29, with status A. The same holder name appears on a separate subject that names the mesylate, and that filing is not in this set. Type II also covers intermediates and finished products, so the subject is checked separately. The file gives no CAS field for independent confirmation.

Why does this Lenvatinib page omit the CDE table?

The October 5, 2026 CDE export contains 23 registrations named 甲磺酸仑伐替尼, with 21 status A and 2 status I. It does not use the free-base name and does not give a CAS number. Those rows describe mesylate registrations and are not mixed into this Lenvatinib dataset.

What does an active Lenvatinib DMF mean?

An A code indicates that DMF 33195 was active in the FDA snapshot. FDA reviews the technical contents in connection with an application that references the DMF. The activity code does not indicate FDA approval, and it does not confirm that the holder will authorize a reference or supply a batch.

What should a buyer verify with the holder of this Lenvatinib DMF?

Confirm DMF 33195, the free-base form and the assay basis, and the manufacturing site that would supply the intended batch. Request the applicable specification and the batch certificate of analysis. If an application will reference the file, ask the holder about a letter of authorization. Do not treat a mesylate, besylate, solvate or named crystal form as this record.

FDA UNII substance record EE083865G2PubChem compound CID 9823820DailyMed: LENVIMA prescribing informationPubChem mesylate record CID 11237762FDA DMF list: Q2 2026 snapshotFDA: Types of Drug Master FilesNMPA CDE API registry: October 5, 2026 exportFDA: Drug Master Files

Data sources

Official substance references, the supplied snapshots and FDA guidance for interpreting the records.

FDA UNII substance record EE083865G2

Open source reference

U.S. Food and Drug Administration

Identifies the free base by CAS 417716-92-8 and UNII EE083865G2, and lists E7080 among the synonyms.

View citation evidence

“417716-92-8”

U.S. Food and Drug Administration

Synonyms and Mappings in FDA UNII record EE083865G2.

PubChem compound CID 9823820

Open source reference

National Center for Biotechnology Information

Supplies the free-base formula and computed molecular weight, and lists deprecated CAS 942407-57-0 for the same substance.

View citation evidence

“426.9 g/mol”

National Center for Biotechnology Information

Molecular Weight in the Computed Properties table for PubChem CID 9823820.

DailyMed: LENVIMA prescribing information

Open source reference

U.S. National Library of Medicine

States that the capsule drug substance is the mesylate salt, gives the salt molecular weight as 522.96, and expresses 4 mg and 10 mg strengths as quantities of the free base.

View citation evidence

“equivalent to 4.90 mg or 12.25 mg of lenvatinib mesylate”

U.S. National Library of Medicine

Section 11, Description, of the LENVIMA labeling hosted by DailyMed.

PubChem mesylate record CID 11237762

Open source reference

National Center for Biotechnology Information

Identifies the mesylate salt by CAS 857890-39-2. That salt is outside this free-base record set.

View citation evidence

“857890-39-2”

National Center for Biotechnology Information

Synonyms listed for PubChem CID 11237762.

FDA DMF list: Q2 2026 snapshot

Open source reference

U.S. Food and Drug Administration

The supplied workbook contains the selected filing at the June 30, 2026 cutoff. The official list page may show a newer quarter.

View citation evidence

“LENVATINIB”

U.S. Food and Drug Administration

Reported SUBJECT of the selected Type II filing in worksheet 2Q2026-EXCEL.

FDA: Drug Master Files

Open source reference

U.S. Food and Drug Administration

Explains that a DMF can be referenced and that FDA reviews its technical contents with the application that cites it.

View citation evidence

“Are neither approved nor disapproved.”

U.S. Food and Drug Administration

FDA explanation of Drug Master Files and review of applications that reference them.

FDA: Types of Drug Master Files

Open source reference

U.S. Food and Drug Administration

Shows why a Type II classification alone does not establish that a filing covers the free base.

View citation evidence

“Drug Substance, Drug Substance Intermediate”

U.S. Food and Drug Administration

FDA Type II Drug Master File category heading.

NMPA CDE API registry: October 5, 2026 export

Open source reference

Center for Drug Evaluation, National Medical Products Administration

The supplied export names all 23 related registrations as the mesylate. Twenty-one are status A and two are status I.

View citation evidence

“甲磺酸仑伐替尼”

Center for Drug Evaluation, National Medical Products Administration

Reported substance name in the supplied eleven-column CDE API registry export.

Continue your Lenvatinib API research

The free table already shows the one Lenvatinib filing whose subject is exactly LENVATINIB. Subscribe to export that FDA row as CSV and to search other API datasets on APIRFQ. The subscription does not add another free-base row from this snapshot.

CSV export requires an active subscription. The Lenvatinib filing in the table is already visible. Already subscribed? Sign in to export it.

Report a data correction

Include the DMF number or the field in question and a link to the supporting source.

Email APIRFQ support